Publication | Closed Access

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation

Medicinal ChemistryPharmaceutical SciencePreclinical Drug EvaluationContinual Reassessment MethodDose EscalationPharmacologyPharmacotherapyDrug DevelopmentMedicineMultitargeted AntifolatePharmacokineticsDrug DiscoveryDrug Resistance